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Little information is currently available regarding the pharmacokinetics (PK) of busulfan in infants and small
children to help guide decisions for safe and efﬁcacious drug therapy. The objective of this study was to
develop an algorithm for individualized dosing of i.v. busulfan in infants and children weighing 12 kg, that
would achieve targeted exposure with the ﬁrst dose of busulfan. Population PK modeling was conducted
using intensive time-concentration data collected through the routine therapeutic drug monitoring of
busulfan in 149 patients from 8 centers. Busulfan PK was well described by a 1-compartment base model with
linear elimination. The important clinical covariates affecting busulfan PK were actual body weight and age.
Based on our model, the predicted clearance of busulfan increases approximately 1.7-fold between 6 weeks to
2 years of life. For infants age <5 months, the model-predicted doses (mg/kg) required to achieve a thera-
peutic concentration at steady state of 600-900 ng/mL (area under the curve range, 900-1350 mM$min) were
much lower compared with standard busulfan doses of 1.1 mg/kg. These results could help guide clinicians
and inform better dosing decisions for busulfan in young infants and small children undergoing hemato-
poietic cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION rates, limitations on blood volumes, and inadequate assay
The pharmacokinetics (PK) and pharmacodynamics of
drugs in infants can differ widely between children and
adults [1-3]. Within the ﬁrst year of life, age-related devel-
opmental changes in physiological and metabolic processes
can lead to signiﬁcantly altered drug disposition [1,4]. In
addition, the relationships among dose, plasma concentra-
tion, and pharmacodynamic effect may be highly variable
across different age groups and disease states. The value of
understanding therapeutic differences in drug response
because of developmental factors is dependent on the ability
to deﬁne a doseeconcentration relationship [5]. Unfortu-
nately, barriers unique to the pediatric population can hinder
PK studies, particularly in infants. Clinical therapeutic trials
are often limited by ethical considerations, low study consentedgments on page 1613.
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Busulfan (Busulfex) is a bifunctional alkylating agent
routinely used in conditioning regimens before hematopoi-
etic cell transplantation (HCT) to treat various childhood
malignant and nonmalignant disorders [7]. Despite the
widespread use of busulfan, PK studies in infants remain
inadequate to ensure safe and efﬁcacious drug therapy. As
deﬁned by drug manufacturers’ guidelines, initial doses of
busulfan are based on actual body weight, with the aim of
achieving an area under the curve (AUC) of 900-1350
mM$min (equivalent to a concentration at steady state [Css]
of 600-900 ng/mL) (Table 1) [7]. However, this dose was
based on the results of a single clinical trial of only 24 chil-
dren undergoing HCT who received busulfan in combination
with cyclophosphamide [7,8]. The patients ranged in age
from 3months to 16 years (mean age, 6.3 years) and included
only 14 children age 4 years [7]. More recently, several
population PK studies in children have shown that individ-
ualized (eg, personalized) model-based algorithms for
busulfan clearance that incorporate body size and/or age
provide improved targeted therapy compared with stratiﬁed
weight- or age-based regimens alone [9-13]. Unfortunately,Transplantation.
Table 1
PK Parameters Used in the Therapeutic Dose Monitoring of Busulfan,
Expressed in Unit Equivalents
PK Parameter Equivalent Value of the Therapeutic Range*
Css, ng/mL 600-900
AUC, mM$min 900-1350
AUC, mg$h/L 3.6-5.4
* Equivalent values reﬂect the therapeutic range for a 6-hour dosing
interval.
Table 2
Patient Demographic and Baseline Characteristics by Study Group
Study
Group A*
Study
Group By
Study
Group Cz
Number 24 24 101
Age, y,
median
(range)
0.8 (0.1-3.0) 0.7 (0.08-1.8) 1 (0.1-3.3)
Age 6 mo, n 4 6 10
Age >6 mo, n 20 18 91
Weight, kg,
median
(range)
8.3 (3-12) 6.9 (3.3-10.3) 9.2 (3.5-12)
Weight 6 kg, n 1 6 14
Weight >6-12 kg, n 23 18 87
Males/females, n4x 11/13 16/8 43/41
Height, cm, median
(range)
70 (51-88) 65 (51-78) 74 (51-123)
BSA, m2, median
(range)
0.4 (0.2-0.6) 0.4 (0.2-0.5) 0.4 (0.2-0.6)
Dose, mg, median
(range)
8.4 (2-17) 7.35 (3.3-11) 20 (3.5-70)
Dose, mg/kg, median
(range)
0.97 (0.67-1.5) 1.1 (0.6-1.1) 4.1 (0.8-7.5)
Dosing interval Every 6 h Every 6 h Every 6 hr
or 24 h
* University of San Francisco Benioff Children’s Hospital.
y Boston Children’s Hospital.
z Combined data from 6 collaborative centers [9]: University Medical
Center Utrecht, Leiden University Medical Center, Royal Manchester Chil-
dren’s Hospital, Newcastle upon Tyne Hospital, University of Manitoba, and
the Children’s Hospital at Westmead, Sydney.
x Sex was not reported in 17 subjects.
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in infants and small children weighing <12 kg, and thus the
appropriateness of extrapolating these dosing algorithms to
infants or very young children remains unclear.
Intervention with HCT very early in life is often consid-
ered critical to the effective treatment of several childhood
diseases, including many immunodeﬁciencies and genetic
metabolic disorders [14-17]. For example, children with
severe combined immunodeﬁciency disease (SCID) usually
require deﬁnitive therapy with HCT soon after diagnosis.
These children typically present early in life (age <6
months). With newborn screening for SCID becoming
increasingly available, children are now being diagnosed in
the ﬁrst 4 weeks of life, allowing the use of HCT at a young
age when outcomes are superior [18]. For children with
Hurler’s disease, a mucopolysaccharidosis disorder, the
younger that a child is treated with HCT (the only effective
treatment currently available), the better the overall
outcome [17]. The inclusion of busulfan in the conditioning
regimens of very young children is often desirable to
promote stem cell engraftment, correct B cell functionality,
and avoid long-term consequences of total body irradiation,
including growth and developmental delay, poor jaw and
tooth development, cataracts, and increased risk of malig-
nancy later in life [19]. Unfortunately, limited busulfan PK
data are available in infants and very small children to guide
dosing and ensure optimal drug therapy. The objective of the
present study was to develop an algorithm for individualized
dosing of busulfan in children weighing <12 kg that would
achieve targeted exposure with the ﬁrst dose of busulfan.PATIENTS AND METHODS
Study Population
This retrospective study used PK data available from routine therapeutic
drug monitoring of busulfan levels in 149 pediatric patients treated with
HCT from multiple study centers. Eligibility criteria for busulfan PK analysis
in this study included (1) an actual body weight 12 kg, (2) related or
unrelated HCT that included i.v. busulfan therapy, and (3) busulfan plasma
timeeconcentration data available for analysis. Busulfan PK data were
provided by 3 different study groups in the United States, Canada, Europe,
and the United Kingdom (Table 2). Speciﬁc centers (n¼ 8) within the 3 study
groups contributing data for analysis included the University of California
San Francisco Benioff Children’s Hospital, Boston Children’s Hospital,
University Medical Center Utrecht, Leiden University Medical Center, Royal
Manchester Children’s Hospital, University of Manitoba, and Children’s
Hospital of Westmead, Sydney. Local Institutional Review Boards approved
this study, and written informed consent to undergo therapy and PK studies
was obtained from all patients and guardians.
The preparative regimen, diagnoses, timing of PK sampling, and bio-
analytical analysis have been described in detail previously [9,20-22]. In
brief, patients underwent HCT for a wide variety of malignant and
nonmalignant pediatric disorders. HCT preparative regimens included
busulfan along with different chemotherapeutic agents varying according to
the study sites and diagnoses. Busulfan was administered i.v. in all subjects.
In the majority of patients, busulfan was administered every 6 hours or
every 24 hours (once daily) over a period of 3-4 days. As part of routine
clinical care, busulfan plasma concentrations were therapeutically moni-
tored and dose adjustments made to achieve individual protocol-speciﬁc
targets.Population PK Analysis
PK model development using busulfan plasma concentrationetime data
was performed using the nonlinear mixed-effects modeling program
NONMEM version 7 (ICON Development Solutions, Ellicott City, MD).
Diagnostic graphics and postprocessing of NONMEM output and simula-
tions were performed using R (R Core Team, Vienna, Australia, 2013, http://
www.R-project.org.) and Xpose statistical software [23]. The ﬁrst-order
conditional estimation method with interaction was used throughout the
model-building process to estimate PK parameters and variability. Model
development was guided by exploratory analysis of the data, changes in the
NONMEM objective function value (OFV), diagnostic plots, and the potential
biological plausibility of a relationship between clinical covariates and PK
parameters. Because many subjects underwent intensive sampling on
multiple occasions, interoccasion variability was investigated. Residual
unexplained variability was characterized by an additive and proportional
error model. Using standard principles of allometric scaling, weight was
built into the base model a priori and scaled to a reference patient with
a median weight of 8 kg [24]. The model was parameterized in terms of
clearance (CL) and volume of distribution in the central compartment (Vc).
Patient-speciﬁc factors considered for covariate testing included age,
height, body surface area, and sex. Different covariate relationships on PK
parameters were investigatedwith power, linear, and exponential functions.
Correlations between covariates were investigated as well. The ﬁnal PK
model was built through the stepwise covariate model-building process of
forward selection and backward elimination of clinical covariates. The
likelihood ratio test was used to assess the signiﬁcance of all covariates in
the ﬁnal model. During forward selection, covariates were univariately
tested and deemed signiﬁcant if the OFV decreased by at least 3.84 (P  .05,
chi-squared test, degrees of freedom [df] ¼ 1) with its inclusion in the
model. During backward elimination, signiﬁcance of the covariates were
conﬁrmed by removing one covariate at a time from the full model, with an
increase in OFV of at least 5.99 (P  .01, chi-squared test, df ¼ 1) required for
retention in the model.
Model Evaluation
The precision of the ﬁnal model parameter estimates was evaluated
using a nonparametric bootstrap approach. A total of 1000 bootstrap data-
sets were generated by repeated sampling with replacement from the
original data, and the ﬁnal PK model was ﬁtted to each of the bootstrap
datasets. The median, 5th, and 95th percentiles were then obtained for each
PK parameter and compared with the ﬁnal model PK estimates. For a visual
predictive check (VPC), 500 datasets using the covariate distributions from
Figure 1. Fraction of busulfan clearance for infants compared to an average 2-
year-old child by change in busulfan clearance versus weight (A) and change in
busulfan clearance versus age (B).
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ﬁnal model and the median, 5th, and 95th percentiles compared with
observed concentrations. Individual VPCs were performed for every-6-hour
dosing and once-daily administration.
Determination of Targeted Dose
Based on our ﬁnal model, simulations were performed to achieve the
conventional therapeutic targets for busulfan exposure. In addition, simu-
lated Css values based on conventional dosing were compared with the
model-based strategy for achieving conventional exposure. The following
model-based equation was used for the simulations:
Dose ðmgÞ ¼ AUCtarget  CLi; where CLi ¼ f ðweight; ageÞ:
Model-based doses were calculated to achieve the midpoint AUC cor-
responding to a targeted Css range for conventional exposure. Conventional
exposure as proposed by the manufacturers’ guidelines was deﬁned as an
AUCtarget of 4.5 mg$h/L (range, 3.6-5.4 mg$h/L) over a 6-hour dosing interval.
This target is equivalent to a Css of 750 ng/mL (range, 600-900 ng/mL) and
an AUC of 1098 mM$min (range, 900-1350 mM$min) or 4.5 mg$h/L (range,
3.6-5.4 mg$h/L). Css was calculated as AUC/dose.
RESULTS
Patient Demographics
Patient demographics and baseline characteristics by
study group are presented in Table 2. In the 149 study
subjects, the overall median age was 0.94 years (11 months;
range, 0.1-3.3 years), with 14% of subjects age <6 months.
Overall median actual body weight was 8 kg (range, 3-12 kg),
and 14% of the children weighed 6 kg. Doses normalized to
body weight were variable, with higher doses reﬂecting
once-daily versus every-6-hour administration.
Population PK Model Building
A total of 1247 quantiﬁable concentrations were available
for population PK modeling and were best described with
a 1-compartment base model with linear elimination. The
range of concentrations was 25-8778 ng/mL. Irrespective of
each individual center-speciﬁc assay,<1% of busulfan plasma
concentrations were below the level of quantiﬁcation and
were included in the analysis. A 1-compartment model
provided an adequate ﬁt to the data. Addition of a second
disposition compartment and/or nonlinear elimination did
not produce any further improvement. Interoccasion
variability improved the model markedly (DOFV >222;
P < 1050).
Separate models were developed for different dosing
schedules to examine potential differences between once-
daily and every-6-hour dosing, however, no differences
were detected. Different residual error models were allowed
for different centers, to accommodate potential between-
center differences in assay errors.
Effects of Covariates on Busulfan Clearance
Important patient-speciﬁc covariates found to signiﬁ-
cantly impact busulfan CL were actual body weight and age.
All covariates identiﬁed were supported by individual
Bayesian PK parameter estimates versus covariate plots.
Implementing allometric scaling of PK parameters greatly
improved the model, however, it was not sufﬁcient to
describe the observed growth-dependent changes in CL in
very young children (Figure 1). Estimated CL values sug-
gested that younger children have lower CL compared with
the values anticipated by allometric scaling only. The addi-
tion of a nonlinear function of CL versus age was imple-
mented to describe maturation of CL, and this function was
signiﬁcant (P < .001) and beneﬁcial for the model. No
signiﬁcant impact of any other covariates on busulfan CL was
identiﬁed.Final Population PK Model
The population PK parameters estimates and their rela-
tive standard errors (SEs; %) from the ﬁnal model are pre-
sented in Table 3. The ﬁnal model for busulfan CL
incorporating both a weight and maturation effect was as
follows:
CL ¼ 2:3L=h 

Matmag þ

1 Matmag


h
1  eðAge  KmatÞ
i 
 ðWeight=8 kgÞ0:75 ;
where 2.3 L/h is the typical value of busulfan CL,Matmag is the
estimated maturation magnitude effect for age on CL, and
Kmat is the maturation rate constant for the effect of age on
CL. The goodness-of-ﬁt plots for the base and ﬁnal model
Table 3
Final Population Pk Model Parameter Estimates and Bootstrap Results
Population PK Parameter Unit Final Model Results Bootstrap Results
Typical Value Estimate* Relative SE, % Median 95% CI
Clearance (CL) L/h 2.3 6 2.3 2.1-2.6
Exponent for effect of weight on CL 0.75 (ﬁxed) d 0.75 (ﬁxed) d
Volume of central compartment (Vc) L/kg 6.4 2 6.4 6.1-6.7
Exponent for effect of weight on Vc 1 (ﬁxed) d 1 (ﬁxed) d
Maturation magnitude (Matmag) Fraction 0.46 9 0.45 0.36-0.55
Maturation rate constant (kmat) 1/y 1.4 27 1.4 0.8-2.3
Interindividual variability (IIV)
IIV for CL, %CVy 25 14 26 23-29
IIV for Vc, %CV 25 20 24 18-29
Correlation of CL and Vc 0.74 20 0.64 0.58-0.69
Residual variability, %CV
Proportional, study group A 8 20 8 5-12
Proportional, study group B 12 17 11 7-16
Proportional, study group C 16 12 16 14-18
Additive, study group A ng/mL 46 9 61 33-84
Additive, study group B ng/mL 63 15 62 39-87
Additive, study group C ng/mL 17 7 17 11-23
* Mean typical value of the PK parameter in the ﬁnal model.
y %CV, ratio of the SD to the mean.
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population-predicted concentrations around the line of
unity, indicating that the data are adequately described by
the ﬁnal model (data not shown). The vast majority (95%) of
conditional weighted residuals fell within 2 standard devi-
ations, demonstrating good predictability of the model. No
trend in the residuals was observed.Model Evaluation
The median PK parameter estimates and 95% conﬁdence
intervals from the bootstrap analysis are presented in Table 3.
Median estimates of PK parameters, interpatient variability,
and residual unexplained variability derived from the boot-
strap analysis were comparable with the typical values
derived from the original population PK analysis. The VPC
showed that the median and percentiles of 500 simulated
datasets captured the median and percentiles of the original
observed PK data well for both the every-6-hours and once-
daily dosing schedules (Figure 2).Model-Based Dosing to Achieve Conventional Therapeutic
Target
Doses (per actual body weight) to achieve conventional
exposure (600-900 ng/mL) were simulated and estimated
using the model-based algorithm. In particular, children
weighing<10 kg required lower doses with themodel-based
algorithm compared with conventional dosing recom-
mending 1.1 mg/kg (Figure 3). Table 4 provides the estimated
doses (mg/kg) required for typical 6-week-old, 3-month-old,
and 6-month-old individuals to achieve therapeutic expo-
sure at steady-state using the model-based algorithm. For
example, the model-predicted dose needed to achieve a Css
of 750 ng/mL for 6-week-old infant weighing 4.5 kgwould be
3.6 mg (0.79 mg/kg), representing a decrease of approxi-
mately 28% compared with conventional dosing. Figure 4
shows conventional dosing versus the model-based algo-
rithm for achieving a Css of 600-900 ng/mL by age.
Compared with model-based dosing, when using the
conventional dosing algorithm, children under approxi-
mately 5 months of age are more likely to achieve Css values
above the recommended threshold of toxicity (900 ng/mL).DISCUSSION
To the best of our knowledge, this is the largest PK anal-
ysis reported to date composed exclusively of children
weighing 12 kg who received busulfan as part of a condi-
tioning regimen for HCT. Before our results, very little
information was available regarding the PK of busulfan in
young infants and small children to help determine initial
doses for drug therapy. In this study, we developed a pop-
ulation PK model for busulfan CL using timeeconcentration
data collected through routine therapeutic drug monitoring
from multiple study centers. Plasma concentrations of
busulfan were well described by a 1-compartment model
with linear elimination. Our covariate analysis identiﬁed
both weight and age as signiﬁcant patient-speciﬁc factors
impacting busulfan CL.
Investigating age-related changes resulting from physio-
logical and enzymatic processes canmake the PKmodeling of
drugs in infants and small children particularly challenging
[5]. Precise quantiﬁcation of maturation processes requires
a large sample size of children with a wide range of weight
and age combinations. The allometric scaling of weight
provides a mechanistic and physiological-based approach
that if used a priori allows for the delineation of the effect of
size from other covariates that demonstrate a high degree of
correlation [25]. By choosing weight as our primary covariate
and by assuming an exponent of 0.75, we were able to
identify the impact of maturation on busulfan CL. Other
investigators may chose to estimate the exponent for the
effect of weight on CL instead of ﬁxing it to the physiological
value of 0.75 [8,9,13,26]. Even though this approach may
provide a good ﬁt to the model and may result in the most
parsimonious model, mechanistic interpretation of such
parameters is limited. By Including both weight and age in
our model accounts not only for changes in drug CL owing to
body size and liver blood ﬂow, but also for the maturation of
enzymes, which is best described as a function of age. In
addition, the use of body surface area has previously been
suggested as a predictor of busulfan CL [10,27]. Body surface
area is a derived parameter from height and weight, and as
such limits the physiological interpretation of such models.
Based on our model, the predicted CL of busulfan
increases by approximately 1.7-fold between 6 weeks and
Figure 3. Model-based estimated dose (mg/kg) required to achieve a thera-
peutic Css of 600-900 ng/mL (solid line). For comparison, the dashed line
represents conventional dosing of 1.1 mg/kg in children weighing <12 kg.
Figure 2. Visual predictive check for every 6-hour dosing (A) and once-daily
administration (B). The solid line represents the data median. The upper and
lower dashed lines are 97.5th and 2.5th data percentiles, respectively. The
upper, middle, and lower shaded areas are simulated 97.5th percentile,
median, and 2.5th percentile with uncertainty, respectively. An appropriate
model ﬁt is indicated if lines are contained within shaded areas.
Table 4
Estimated Doses for A Typical 6-Week-Old, 3-Month-Old, and 6-Month-Old
Individual to Achieve Therapeutic Exposure at Steady-State Using the
Model-Based Algorithim*
Therapeutic Target
(Css 600-900 ng/mL)y
Age of Individual
6 Weeks 3 Months 6 Months
Weight, kg 4.5 6.4 8.4
Dose, mg/kg 0.79 0.84 0.97
Dose, mg 3.6 5.4 8.1
* Based on an “average” estimate of weight per age, according to the
World Health Organization growth standards for infants and children age
0-2 years.
y Doses are based on achievement of the desired therapeutic Css over
a 6-hour dosing interval. An estimated Css of 750 ng/mL (range, 600-900
ng/mL) is equivalent to an AUC of 1098 uM$min (range, 900-1350 uM$min)
or 4.5 mg$hr/L (range, 3.6-5.4 mg$hr/L).
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conversion in the liver through conjugation with glutathione
by glutathione S-transferase (GST) enzymes, predominantly
via GSTA1, and minor contributions from GSTM1 and GSTP1
[28,29]. The GST enzymes involved in busulfan metabolism
can undergo signiﬁcant changes in activity and/or expression,
increasing gradually over the ﬁrst 2 years of life [1,28,30]. It is
plausible that the variability in PK among infants, children,
and adolescents/adults is related to differences in GSTactivity
and/or expression with age. No formal studies investigating
the relationship between busulfan drug levels and the
ontogeny of hepatic GSTs in the very young have been re-
ported to date. Moreover, given that busulfan undergoesextensivemetabolic conversion in the liver, it is plausible that
prematurity may have a signiﬁcant effect on busulfan expo-
sure. Unfortunately, we were unable to obtain individual
information on gestational age, and thus the appropriateness
of ourmodel for preterm infants is unknown, and it should be
applied with caution in this population.
Strategies for the therapeutic drug monitoring of
busulfan, such as Css or AUC accumulative exposure over the
entire course of therapy, differ among treatment centers
[7,31]. The incorporation of age and weight relationships into
our model for busulfan CL ensures the same likelihood of
reaching the desired therapeutic exposure in all patients,
irrespective of the selected target goal. Particularly for chil-
dren age <5 months, the model-based algorithm demon-
strates signiﬁcant improvement over conventional dosing,
given that these children are more likely to experience drug
concentrations above the therapeutic threshold for toxicity
with standard dosing. Themodel-predicted doses required to
achieve the therapeutic range of 600-900 ng/mL in children
age <5 months are much lower than the standard dose of
1.1 mg/kg. Improved dosing strategies for busulfan in infants
can be expected to reduce morbidity and mortality through
improved rates of stem cell engraftment and less drug-
related toxicity (eg, hepatic sinusoidal obstructive syn-
drome). Furthermore, infant survivors of HCT can experience
Figure 4. Plot demonstrating estimated Css with conventional dosing versus
the model-based algorithm for achieving a therapeutic target of 600-900 ng/
mL by age. The currently recommended dose (1.1 mg/kg) is shown for refer-
ence (horizontal dashed line).
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chemotherapy, including impaired pulmonary function,
hypothyroidism, metabolic syndrome, and cognitive
impairment [32]. Individualized busulfan therapy has the
potential to minimize the risk of severe long-term compli-
cations attributable to chemotherapy in survivors of pedi-
atric HCT and thereby improve overall quality of life. This is
particularly true for patients with nonmalignant disorders in
which, depending on the disease and goal for degree of stem
cell chimerism, lower doses of busulfan may be feasible.
Although the PK parameters were well estimated by our
ﬁnal model, the between-subject variability remained
modest, at approximately 25%. This ﬁnding suggests this
other covariates not evaluated in this analysis also may be
important determinants of busulfan CL. Physiological
changes induced by speciﬁc disease states, including inborn
errors of metabolism and thalassemia, have been demon-
strated to alter busulfan CL [33-35]. Given the heterogeneity
of diseases included in our study population, covariate
analysis of different disease groups was not feasible. Simi-
larly, the impact of medications previously shown to alter
busulfan PK through the induction or inhibition of GSTs
could not be adequately investigated. Information on the
coadministration of the known enzyme-inducer phenytoin
was not available for a majority of subjects. Drugedrug
interactions among busulfan, azole antifungal agents, and
metronidazole have been shown to alter busulfan CL through
the inhibition of metabolic enzymes [36,37], but this could
not be evaluated in the present study.
Other potential factors not explored in this study include
genetic variants of genes involved in busulfan metabolism
and disposition. In vitro studies have shown variants in
GSTP1 result in functional alterations in activity leading to
decreased enzymatic activity [38]. Clinically, the impact of
several GST genetic variants on busulfan exposure has been
investigated, with variable results reported [39-42]. Finally,
genomic studies in children can be difﬁcult, given the effectsof ontogeny on drug-metabolizing enzymes, and require
careful consideration [43].
Model validation, including prospective evaluation, is
critical to ensure the predictability of any model. A large
number of subjects spanning awide range of ages is required
to adequately investigate the effects of maturation on meta-
bolic pathways. Thus, for this analysis, we elected to build the
model using all data available (versus data splitting) and to
perform model evaluation using a nonparametric bootstrap
approach. We are currently collecting additional retrospec-
tive data,whichwill serve as an external validation dataset. In
addition, we are in the early stages of planning a formal
prospective evaluation of the busulfan algorithm in very
young children undergoing HCTearly in life for the treatment
of SCID. This work will be presented in future reports.
In summary, we have developed a model for busulfan CL
based on age andweight that can be used to determine initial
doses in infants and young children weighing 12 kg.
Compared with the conventional dosing guidelines, our
individualized model-based algorithm may provide an
improved dosing strategy for achieving targeted busulfan
exposure in infants.ACKNOWLEDGMENTS
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